Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) have received an average recommendation of “Moderate Buy” from the five analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $22.50.

TENX has been the subject of several research analyst reports. Lifesci Capital raised shares of Tenax Therapeutics to a “strong-buy” rating in a research report on Thursday. William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Tenax Therapeutics in a research note on Monday, December 22nd. Finally, Guggenheim restated a “buy” rating and set a $25.00 price objective (up from $14.00) on shares of Tenax Therapeutics in a report on Wednesday, December 17th.

Institutional Investors Weigh In On Tenax Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new position in shares of Tenax Therapeutics in the 3rd quarter worth about $92,000. Letko Brosseau & Associates Inc. acquired a new position in shares of Tenax Therapeutics in the 4th quarter valued at about $130,000. Corient Private Wealth LLC purchased a new stake in shares of Tenax Therapeutics during the 4th quarter worth about $151,000. Quadrature Capital Ltd acquired a new stake in Tenax Therapeutics during the 4th quarter worth approximately $252,000. Finally, Goldman Sachs Group Inc. acquired a new stake in Tenax Therapeutics during the 4th quarter worth approximately $273,000. 1.67% of the stock is currently owned by institutional investors and hedge funds.

Tenax Therapeutics Trading Up 2.5%

TENX traded up $0.36 during midday trading on Friday, hitting $14.55. The company’s stock had a trading volume of 48,363 shares, compared to its average volume of 317,220. Tenax Therapeutics has a 52-week low of $4.63 and a 52-week high of $18.38. The firm has a 50-day moving average price of $13.30 and a two-hundred day moving average price of $9.90. The firm has a market cap of $90.79 million, a P/E ratio of -10.72 and a beta of 1.41.

Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings data on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($1.26) by $0.88. On average, equities analysts expect that Tenax Therapeutics will post -0.88 EPS for the current year.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.